Literature DB >> 33579286

Integrated analysis of differentially expressed genes and construction of a competing endogenous RNA network in human Huntington neural progenitor cells.

Xiaoping Tan1, Yang Liu1, Taiming Zhang1, Shuyan Cong2.   

Abstract

BACKGROUND: Huntington's disease (HD) is one of the most common polyglutamine disorders, leading to progressive dyskinesia, cognitive impairment, and neuropsychological problems. Besides the dysregulation of many protein-coding genes in HD, previous studies have revealed a variety of non-coding RNAs that are also dysregulated in HD, including several long non-coding RNAs (lncRNAs). However, an integrated analysis of differentially expressed (DE) genes based on a competing endogenous RNA (ceRNA) network is still currently lacking.
METHODS: In this study, we have systematically analyzed the gene expression profile data of neural progenitor cells (NPCs) derived from patients with HD and controls (healthy controls and the isogenic controls of HD patient cell lines corrected using a CRISPR-Cas9 approach at the HTT locus) to screen out DE mRNAs and DE lncRNAs and create a ceRNA network. To learn more about the possible functions of lncRNAs in the ceRNA regulatory network in HD, we conducted a functional analysis of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) and established a protein-protein interaction (PPI) network for mRNAs interacting with these lncRNAs.
RESULTS: We identified 490 DE mRNAs and 94 DE lncRNAs, respectively. Of these, 189 mRNAs and 20 lncRNAs were applied to create a ceRNA network. The results showed that the function of DE lncRNAs mainly correlated with transcriptional regulation as demonstrated by GO analysis. Also, KEGG enrichment analysis showed these lncRNAs were involved in tumor necrosis factor, calcium, Wnt, and NF-kappa B signaling pathways. Interestingly, the PPI network revealed that a variety of transcription factors in the ceRNA network interacted with each other, suggesting such lncRNAs may regulate transcription in HD by controlling the expression of such protein-coding genes, especially transcription factors.
CONCLUSIONS: Our research provides new clues for uncovering the mechanisms of lncRNAs in HD and can be used as the focus for further investigation.

Entities:  

Keywords:  Bioinformatics; Huntington disease; RNA; ceRNA; lncRNA

Year:  2021        PMID: 33579286      PMCID: PMC7881634          DOI: 10.1186/s12920-021-00894-2

Source DB:  PubMed          Journal:  BMC Med Genomics        ISSN: 1755-8794            Impact factor:   3.063


  77 in total

1.  MicroRNA-mediated conversion of human fibroblasts to neurons.

Authors:  Andrew S Yoo; Alfred X Sun; Li Li; Aleksandr Shcheglovitov; Thomas Portmann; Yulong Li; Chris Lee-Messer; Ricardo E Dolmetsch; Richard W Tsien; Gerald R Crabtree
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

2.  Wild-type huntingtin protects neurons from excitotoxicity.

Authors:  Blair R Leavitt; Jeremy M van Raamsdonk; Jacqueline Shehadeh; Herman Fernandes; Zoe Murphy; Rona K Graham; Cheryl L Wellington; Lynn A Raymond; Michael R Hayden
Journal:  J Neurochem       Date:  2006-01-17       Impact factor: 5.372

Review 3.  Long non-coding RNAs in Huntington's disease neurodegeneration.

Authors:  Rory Johnson
Journal:  Neurobiol Dis       Date:  2011-12-14       Impact factor: 5.996

4.  Long noncoding RNA as modular scaffold of histone modification complexes.

Authors:  Miao-Chih Tsai; Ohad Manor; Yue Wan; Nima Mosammaparast; Jordon K Wang; Fei Lan; Yang Shi; Eran Segal; Howard Y Chang
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

5.  A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?

Authors:  Leonardo Salmena; Laura Poliseno; Yvonne Tay; Lev Kats; Pier Paolo Pandolfi
Journal:  Cell       Date:  2011-07-28       Impact factor: 41.582

Review 6.  Basic biology and therapeutic implications of lncRNA.

Authors:  O Khorkova; J Hsiao; C Wahlestedt
Journal:  Adv Drug Deliv Rev       Date:  2015-05-27       Impact factor: 15.470

7.  Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals.

Authors:  Mitchell Guttman; Ido Amit; Manuel Garber; Courtney French; Michael F Lin; David Feldser; Maite Huarte; Or Zuk; Bryce W Carey; John P Cassady; Moran N Cabili; Rudolf Jaenisch; Tarjei S Mikkelsen; Tyler Jacks; Nir Hacohen; Bradley E Bernstein; Manolis Kellis; Aviv Regev; John L Rinn; Eric S Lander
Journal:  Nature       Date:  2009-02-01       Impact factor: 49.962

8.  Regional and cellular gene expression changes in human Huntington's disease brain.

Authors:  Angela Hodges; Andrew D Strand; Aaron K Aragaki; Alexandre Kuhn; Thierry Sengstag; Gareth Hughes; Lyn A Elliston; Cathy Hartog; Darlene R Goldstein; Doris Thu; Zane R Hollingsworth; Francois Collin; Beth Synek; Peter A Holmans; Anne B Young; Nancy S Wexler; Mauro Delorenzi; Charles Kooperberg; Sarah J Augood; Richard L M Faull; James M Olson; Lesley Jones; Ruth Luthi-Carter
Journal:  Hum Mol Genet       Date:  2006-02-08       Impact factor: 6.150

9.  Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2017-10-01       Impact factor: 3.848

10.  Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.

Authors:  C Zuccato; A Ciammola; D Rigamonti; B R Leavitt; D Goffredo; L Conti; M E MacDonald; R M Friedlander; V Silani; M R Hayden; T Timmusk; S Sipione; E Cattaneo
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

View more
  1 in total

1.  Bioinformatics Analysis of the Interaction of miRNAs and piRNAs with Human mRNA Genes Having di- and Trinucleotide Repeats.

Authors:  Ayaz Belkozhayev; Raigul Niyazova; Cornelia Wilson; Nurlan Jainakbayev; Anna Pyrkova; Yeldar Ashirbekov; Aigul Akimniyazova; Kamalidin Sharipov; Anatoliy Ivashchenko
Journal:  Genes (Basel)       Date:  2022-04-29       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.